Idorsia Ltd (IDIA.SW) today announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback